Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BLISOVI FE 1.5/30 vs AUROVELA 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Blisovi Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). It inhibits ovulation via suppression of gonadotropins (FSH and LH). Additionally, it increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial development, reducing implantation likelihood.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH, LH) release, inhibiting ovulation, altering cervical mucus, and reducing endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy,Oral contraception
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets (iron-free).
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. Each tablet contains ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg.
Ethinyl estradiol: terminal half-life ~17 hours (range 13–27 h) with single dose; for norethindrone: ~8–11 hours. Clinical context: Steady-state achieved within ~7–10 days; contraceptive efficacy maintained with once-daily dosing.
Norethindrone: ~8–11 hours (terminal); ethinyl estradiol: ~13–19 hours (terminal). Steady-state achieved within 5–7 days.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential for iron accumulation.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential fluid retention and hypertension.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. The risk increases with age and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this product.
FDA Pregnancy Category X. Use is contraindicated in pregnant women because drospirenone/ethinyl estradiol can cause fetal harm. There is no indication for use in pregnancy. If pregnancy occurs during treatment, the drug should be discontinued immediately. Epidemiologic studies have not revealed an increased risk of birth defects in infants born to women who inadvertently used oral contraceptives early in pregnancy. However, drospirenone is a progestin with antiandrogenic activity, and animal studies have shown teratogenic effects including urogenital tract abnormalities at high doses.
First trimester: No increased risk of major birth defects based on large epidemiological studies. Second and third trimesters: Associated with increased risk of intrauterine growth restriction (IUGR), preterm birth, and gestational hypertension if hormonal exposure continues. Close fetal monitoring recommended.
BLISOVI FE 1.5/30 is a combination oral contraceptive containing ethinylestradiol and norethindrone acetate. It is primarily used for contraception and acne treatment. The iron component (ferrous fumarate) is not intended for contraceptive effect but to offset menstrual blood loss. Monitor for thromboembolic events, especially in smokers over 35. Use caution in patients with migraine with aura, hypertension, or liver disease. Drug interactions with rifampin, certain anticonvulsants, and St. John's wort may reduce contraceptive efficacy.
AUROVELA 1/20 (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) is a monophasic oral contraceptive. Advise patients to take at the same time daily to maintain consistent hormone levels. Missed pill protocol: if one pill is missed, take it as soon as remembered; if two or more are missed, use backup contraception for 7 days. Monitor for breakthrough bleeding, especially in the first 3 cycles. Contraindicated in smokers over 35, hypertension, history of thromboembolism, migraine with aura, or liver disease.
No interactions on record
No interactions on record
BLISOVI FE 1.5/30 and AUROVELA 1/20 are distinct pharmacological agents. BLISOVI FE 1.5/30 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancy. AUROVELA 1/20 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyOral contraception. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. BLISOVI FE 1.5/30 carries a safety status of Category C, whereas AUROVELA 1/20 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Ethinyl estradiol is metabolized primarily via CYP3A4; norethindrone is metabolized via reduction and conjugation, with some involvement of CYP3A4.
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes first-pass metabolism. Norethindrone: primarily metabolized by CYP3A4, also undergoes first-pass metabolism.
Renal: ~60% (ethinyl estradiol metabolites as glucuronide/sulfate conjugates, norethindrone metabolites). Fecal: ~40% (biliary excretion of conjugates, with some enterohepatic recirculation).
Renal (30–40% as metabolites, <5% unchanged); biliary/fecal (40–60% as metabolites).
Ethinyl estradiol: ~97% bound to albumin (specifically to albumin, with some binding to SHBG). Norethindrone: ~61% bound to albumin, ~36% to SHBG. Iron: >99% bound to transferrin and ferritin. Folic acid: ~50–60% bound to plasma proteins (mainly albumin).
Norethindrone: ~61% bound to albumin, 36% to SHBG; ethinyl estradiol: ~98% bound to albumin.
Ethinyl estradiol: Vd ~2.7–4.8 L/kg (large, reflecting extensive tissue distribution). Norethindrone: Vd ~3.6–4.3 L/kg. Clinical meaning: large Vd indicates extensive extravascular binding (e.g., fat stores, steroid receptors). Iron: mainly in erythrocytes and reticuloendothelial system; Vd not typically reported. Folic acid: total body folate ~500–20,000 µg, with Vd ~0.6 L/kg (reflects distribution into tissues).
Norethindrone: ~2.5–4 L/kg; ethinyl estradiol: ~2.5–4 L/kg. Distribution into breast milk and body tissues.
Oral ethinyl estradiol: ~38–48% (first-pass metabolism). Norethindrone: ~64% (high first-pass). Folic acid: ~76–93% (dose-dependent; reduced when taken with food). Iron (ferrous fumarate): ~10–20% (varies with iron stores; increased in deficiency).
Oral: norethindrone ~64%, ethinyl estradiol ~45–55% due to first-pass metabolism.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate hepatic impairment; monitor liver function.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). Use with caution in Child-Pugh A or B; monitor liver function and consider alternative contraception if liver disease is active.
Not indicated for use in pediatric females before menarche. Safety and efficacy in adolescents have not been established; use is generally not recommended.
Not indicated for use before menarche. For post-menarcheal adolescents, same dose as adults: one tablet orally once daily.
No specific dose adjustment for geriatric use. Consider increased risk of thromboembolic disorders and monitor accordingly.
Not indicated for use after menopause. For perimenopausal women, same dose as adults until menopause; monitor for thromboembolic risk due to age and comorbidities.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptive use. Risk increases with age and amount smoked, especially in women over 35.
Food does not significantly affect absorption of the hormonal components. Grapefruit juice may inhibit metabolism and increase estrogen levels; avoid large amounts. No specific dietary restrictions. Iron tablets may cause gastrointestinal upset; taking with food may help.
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. High-fat meals can increase drug absorption but not clinically relevant. Alcohol does not interact directly but may impair adherence.
Small amounts of contraceptive steroids have been identified in breast milk, with about 0.02% of the maternal dose of ethinyl estradiol transferred to the infant via milk. The M/P ratio for drospirenone is approximately 0.4–0.6. Combination oral contraceptives may reduce milk production and composition, and their use during breastfeeding is generally not recommended until weaning or at least 6 months postpartum if the infant is fully nursing. Alternative contraception methods are preferred during lactation.
Excreted in breast milk in small amounts (M/P ratio ~0.3). Not known to cause adverse effects in nursing infants at typical doses. Use with caution; may reduce milk production.
There are no recommended dose adjustments for use during pregnancy because the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, decreased protein binding, enhanced clearance) can reduce steroid hormone levels, potentially diminishing efficacy if used inadvertently. Therefore, if pregnancy occurs, discontinue the drug; no dose adjustment is applicable as the drug should not be used.
No dose adjustment required for Auvela 1/20; however, current guidelines recommend discontinuing combination hormonal contraceptives as soon as pregnancy is confirmed due to theoretical risks. Progestin-only or non-hormonal methods are preferred during pregnancy.
Take one tablet daily at the same time each day. The first 21 tablets are active hormones; the last 7 are iron tablets.,If you miss a dose, refer to the package instructions. Missing pills increases risk of pregnancy.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,Contact your healthcare provider if you experience severe headaches, chest pain, leg pain, vision changes, or jaundice.,This medication does not protect against HIV or other sexually transmitted infections.,Inform your doctor about all medications you are taking, including over-the-counter drugs and supplements.,The iron tablets may cause black or dark stools; this is harmless.,If you experience persistent vomiting or diarrhea, use additional contraception.
Take one tablet daily at the same time, preferably with food to reduce nausea.,If you miss a pill, refer to the package insert for specific instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding; these usually improve after 2-3 cycles.,Do not smoke while taking this medication due to increased risk of blood clots.,This medication does not protect against sexually transmitted infections (STIs).,Contact your healthcare provider if you experience severe headache, chest pain, leg pain/swelling, or vision changes.